RETTE SYNDROME RESEARCH TRUST

AWARDS BY YEAR

TOTAL AWARDS $62 MILLION (2008-2021 YTD)
2021 (to date)

Antonio Bedalov / Kyle Fink
Fred Hutchinson Cancer Research Institute / University of California Davis
Reactivation of MECP2
$1,090,919

Bryce Reeve, PhD
Duke University School of Medicine
Development of the Observer-Reported Communication Ability (ORCA) for Rett Syndrome
$15,294

Jackson Laboratories
Testing of siRNA compounds from Khvorova lab for MECP2 Duplication Syndrome
$362,930

TOTAL AWARDS $1,469,143

Due to the global pandemic and the ensuing fundraising uncertainties we were cautious in taking on additional commitments. Furthermore we undertook a detailed analysis of our portfolio and were able to reduce our commitments by $6 million. This reduction allows us to focus our resources on curative projects with the greatest likelihood of success in the nearer term.

2020

DSG
Development of the Rett Syndrome Global Registry
$693,000

James Wilson, MD, PhD
University of Pennsylvania
MECP2 gene therapy for Rett Syndrome
$380,686

Clinical Trial Consortium
David Lieberman, MD, PhD
Boston Children's Hospital
$94,176

Bryce Reeve, PhD
Duke University School of Medicine
Development of the Observer-Reported Communication Ability (ORCA) for Rett Syndrome
$72,225

Citizen
Pilot Study for Digital Natural History Study
$34,885

Sasha Djukic, MD, PhD
Albert Einstein College of Medicine
Support for continuing work at the Rett Syndrome Center
$25,000

TOTAL AWARDS $1,299,972

2019

Adrian Bird, PhD / Michael Greenberg, PhD / Gail Mandel, PhD
University of Edinburgh / Harvard University / Oregon Health and Sciences University
MECP2 Consortium
$3,359,054

James Wilson, MD, PhD
University of Pennsylvania
MECP2 gene therapy for Rett Syndrome
$765,607

TOTAL AWARDS $8,570,181
James Wilson, MD, PhD
University of Pennsylvania
MECP2 gene therapy for Rett Syndrome, vector production
$37,999

Stuart Cobb, PhD / Chris Sibley, PhD
University of Edinburgh
RNA trans-splicing therapy in Rett Syndrome
$235,950

Harvard Stem Cell Institute
Support for development of patient derived induced pluripotent stem cell lines
$101,912

Michael Elowitz, PhD
California Institute of Technology
A system for dosage-independent control of MECP2 expression in Rett Syndrome gene therapy
$212,374

Peter Glazer, PhD / Mark Saltzman PhD
Yale University
PNA nanoparticles for gene editing of Rett Syndrome
$275,000

Alanna Schepartz, PhD
Yale University
Evaluating cell-permeant miniature proteins (CPMPs) as a strategy for delivering functional MECP2 into model cells and neurons
$297,716

Joost Gribnau, PhD
Erasmus Medical Center
Human in vitro models for X chromosome reactivation
$401,000

Antonio Bedalov, PhD
Fred Hutchinson Cancer Research Center
Mouse model maintenance
$20,000

Thorsten Stafforst, PhD
University of Tubingen
RNA editing for MECP2 mutations via RESTORE
$359,856

Joseph Jacobson, PhD
Massachusetts Institute of Technology
Correction of MECP2 mutations with engineered ScCas 9 base editors
$50,000

The Jackson Laboratory
Generation and phenotypic assessment of mouse models for Rett Syndrome
$417,680

Coriell Institute
Rett Syndrome biorepository
$135,000

Emerald Innovations
Passive monitoring of Rett patients with Emerald
$164,670

Beth McCormick, PhD
University of Massachusetts Medical School
Microbiome study for the advancement of novel nutritional supplements
$520,316

Sasha Djukic, MD, PhD
Albert Einstein School of Medicine
Support for continuing work at the Rett Syndrome Center
$75,000

Miscellaneous Pilot Studies
$135,522

Ronald Cohn, PhD
The Hospital for Sick Children
Interrogation of genome editing strategies as a therapeutic modality for MECP2 Duplication Syndrome
$570,000

Anastasia Khvorova, PhD
University of Massachusetts Medical School
Development of siRNA based compounds to potently silence MECP2 towards the treatment of MECP2 Duplication Syndrome
### 2018

#### Jonathan Watts, PhD / Scot Wolfe, PhD / Eric Sontheimer, PhD / Anastasia Khvorova, PhD
University of Massachusetts Medical School
RNA and genome editing for treatment of Rett Syndrome
$2,403,735

#### Guoping Feng, PhD / Feng Zhang, PhD / Robert Desimone, PhD
Massachusetts Institute of Technology / Broad Institute / Harvard University
RNA-editing as a gene therapy approach for Rett Syndrome
$2,332,000

#### Beam Therapeutics
Developing a pre-clinical DNA base editing program to precisely correct the genetic cause of Rett Syndrome in the central nervous system
$1,870,660

#### John Sinnamon, PhD
Oregon Health and Science University
New editing enzymes for RNA
$345,000

#### Peter Beal, PhD
University of California, Davis
New molecular tools for directed editing of MECP2 mutations associated with Rett Syndrome
$563,870

#### Stuart Cobb, PhD / Adrian Bird, PhD
University of Edinburgh
Gene Therapy Consortium 2.0
$653,856

#### Stuart Cobb, PhD
University of Edinburgh
Purchase of qPCR machine
$13,945

#### Andrea Cerase, PhD
Queen Mary University of London
Reactivation of MECP2 and CDKL5 genes by functional deactivation of Xist RNA
$351,022

### TOTAL AWARDS $9,956,283

### 2017

#### James Wilson, MD, PhD
University of Pennsylvania
Gene therapy consortium
$1,585,886

#### Katherin Meyer, PhD
Nationwide Children's Hospital
Optimizing gene therapy for Rett Syndrome
$152,489

#### Jonathan Watts, PhD / Scot Wolfe, PhD / Eric Sontheimer, PhD / Anastasia Khvorova, PhD
University of Massachusetts Medical School
Gene Therapy Consortium Vector Core
$131,243

#### Allan Jacobson, PhD / Jonathan Watts, PhD
University of Massachusetts Medical School
Read-through of premature termination codons for treatment of Rett Syndrome
$323,000

#### Antonio Bedalov
Fred Hutchinson Cancer Research Institute
Reactivation of MECP2
$38,000

#### Clinical Trial Consortium
David Lieberman, MD, PhD
Boston Children's Hospital
$74,792

#### Laurel Joy Gabard-Durnam, PhD
Harvard University
Post Doctoral Fellowship, Autism Science Foundation
$17,500

#### Hassan Ghasemzadeh, PhD
Washington State University
Pilot study to examine gait patterns in Rett Syndrome
$10,000

#### Sasha Djukic, MD, PhD
Albert Einstein College of Medicine
Support for continuing work at the Rett Syndrome Center
$75,000

#### Huda Zoghbi, MD, PhD
Baylor College of Medicine
A forward genetic screen to identify druggable modulators of MECP2 levels
$752,660

### TOTAL AWARDS $6,166,762
Katherin Meyer, PhD
Nationwide Children's Hospital
A gene therapy consortium to develop and evaluate gene therapy approaches in Rett Syndrome
$68,515

Stuart Cobb, PhD
University of Glasgow
Additional support for RNA-trans splicing efforts in Rett Syndrome
$290,000

Rudolf Jaenisch, MD
Whitehead Institute for Biomedical Research
Reactivation of MECP2 with epigenome editing tools to rescue Rett Syndrome
$599,850

Benjamin Philpot, PhD
University of North Carolina Chapel Hill
Pilot study for reactivation of silenced MECP2 by artificial transcription factors
$145,443

Q State Biosciences
Development of an in-vitro cell system for discovering and evaluating the effects of therapeutic candidates on neurons produced using Rett patient iPS cells
$498,141

Michael Greenberg, PhD
Harvard University
Development of an in-vitro cell system for discovering and evaluating the effects of therapeutic candidates on neurons produced using Rett patient iPS cells
$55,826

Clinical Trial Consortium
Daniel Tarquinio, DO
Center for Rare Neurological Diseases
$495,000

Adrian Bird, PhD / Michael Greenberg, PhD / Gail Mandel, PhD
University of Edinburgh / Harvard University / Oregon Health and Sciences University
MECP2 Consortium
$3,454,921

Stuart Cobb, PhD / Steve Gray, PhD / Brian Kaspar, PhD / Gail Mandel, PhD / Alysson Muotri, PhD
University of Glasgow / University of North Carolina Chapel Hill / Nationwide Children's Hospital / Oregon Health and Science University / University of California San Diego
A gene therapy consortium to develop and evaluate gene therapy approaches in Rett Syndrome
$1,450,275

Clinical Trial Consortium
David Lieberman, MD, PhD
Boston Children's Hospital
$395,000

Clinical Trial Consortium
Eric Marsh, MD, PhD
Children's Hospital of Philadelphia
$487,715

Clinical Trial Consortium
Alan Percy, MD, PhD
University of Alabama Birmingham
$485,000

Clinical Trial Consortium
Jeffrey Neul, MD, PhD
Vanderbilt University Medical Center
$495,000

Sasha Djukic, MD, PhD
Albert Einstein College of Medicine
Support for continuing work at the Rett Syndrome Center
$103,000

Huda Zoghbi, MD
Baylor College of Medicine
Investigating the potential of antisense oligonucleotide therapy for MECP2 Duplication Syndrome
$299,897

TOTAL AWARDS $7,571,438

2016

Stuart Cobb, PhD
University of Glasgow
Scientific support for gene therapy, splicing therapy and protein therapy programmes in Rett Syndrome
$210,000

Stuart Cobb, PhD
University of Glasgow
Optimizing MECP2 trans-splicing for human translation
$330,804

Alysson Muotri
University of California San Diego
A drug-screening platform using MECP2-deficient human neurons and preclinical testing
$1,001,000
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Project Description</th>
<th>Award Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antonio Bedalov, PhD</td>
<td>Fred Hutchinson Cancer Research Center</td>
<td>Genetic and pharmacologic reactivation of MeCP2 on the silent X-chromosome as a therapeutic approach to Rett Syndrome</td>
<td>$824,575</td>
</tr>
<tr>
<td>David Katz</td>
<td>Case Western Reserve University School of Medicine</td>
<td>Preclinical studies of LM22A-4 in mouse models of Rett Syndrome</td>
<td>$250,000</td>
</tr>
<tr>
<td>ArmaGen, Inc.</td>
<td>Massachusetts General Hospital / Harvard University</td>
<td>Treating Rett Syndrome by targeting the Xist interactome</td>
<td>$125,000</td>
</tr>
<tr>
<td>Joost Gribnau, PhD</td>
<td>Erasmus MC</td>
<td>Reversal of Rett phenotype: A screen for compounds that enhance KCC2 expression</td>
<td>$180,000</td>
</tr>
<tr>
<td>Neurolixis, PhD</td>
<td>University of North Carolina</td>
<td>Clinical development of NLX-101 in Rett Syndrome</td>
<td>$530,000</td>
</tr>
<tr>
<td>Mark Zylka, PhD</td>
<td>University of North Carolina</td>
<td>High throughput screen to identify drugs that normalize long gene expression in Rett Syndrome model neurons</td>
<td>$400,000</td>
</tr>
<tr>
<td>Andrew Napper, PhD</td>
<td>Nemours duPont Pediatrics</td>
<td>Discovery and in vivo characterization of compounds promoting MECP2 read-through</td>
<td>$230,101</td>
</tr>
<tr>
<td>Michael Greenberg, PhD</td>
<td>Harvard University</td>
<td>Identifying therapeutics for treating Rett Syndrome using nuclear size as a proxy for long gene mis-regulation</td>
<td>$110,000</td>
</tr>
<tr>
<td>O State Biosciences</td>
<td>University of Texas Southwestern Medical Center</td>
<td>Development of an in-vitro cell system for discovering and evaluating the effects of therapeutic candidates on neurons produced using Rett patient iPS cells</td>
<td>$330,000</td>
</tr>
<tr>
<td>Miscellaneous Pilot Projects</td>
<td></td>
<td>Exploration of the impact of 2-hydroxypropyl-β-cyclodextrin treatment on lifespan and brain cholesterol metabolism in male mecp2 deficient mice</td>
<td>$156,180</td>
</tr>
<tr>
<td>Sasha Djukic, MD, PhD</td>
<td>Albert Einstein College of Medicine</td>
<td>Support for continuing work at the Rett Syndrome Center</td>
<td>$84,000</td>
</tr>
<tr>
<td>Alysson Muotri</td>
<td>University of California San Diego</td>
<td>Role of an autism-related cytokine in a genetic model of ASD (Autism Science Foundation)</td>
<td>$12,500</td>
</tr>
<tr>
<td>David Katz</td>
<td>Case Western Reserve University School of Medicine</td>
<td>Preclinical studies of LM22A-4 in mouse models of Rett Syndrome</td>
<td>$250,000</td>
</tr>
<tr>
<td>ArmaGen, Inc.</td>
<td>Massachusetts General Hospital / Harvard University</td>
<td>Treating Rett Syndrome by targeting the Xist interactome</td>
<td>$125,000</td>
</tr>
<tr>
<td>Joost Gribnau, PhD</td>
<td>Erasmus MC</td>
<td>Reversal of Rett phenotype: A screen for compounds that enhance KCC2 expression</td>
<td>$180,000</td>
</tr>
<tr>
<td>Neurolixis, PhD</td>
<td>University of North Carolina</td>
<td>Clinical development of NLX-101 in Rett Syndrome</td>
<td>$530,000</td>
</tr>
<tr>
<td>Mark Zylka, PhD</td>
<td>University of North Carolina</td>
<td>High throughput screen to identify drugs that normalize long gene expression in Rett Syndrome model neurons</td>
<td>$400,000</td>
</tr>
<tr>
<td>Andrew Napper, PhD</td>
<td>Nemours duPont Pediatrics</td>
<td>Discovery and in vivo characterization of compounds promoting MECP2 read-through</td>
<td>$230,101</td>
</tr>
<tr>
<td>Stuart Cobb, PhD</td>
<td>University of Glasgow</td>
<td>Spliceosome-mediated RNA trans-splicing therapy in Rett Syndrome</td>
<td>$86,208</td>
</tr>
<tr>
<td>Stephen Turley, PhD / Adam Lopez, PhD</td>
<td>University of Texas Southwestern Medical Center</td>
<td>Exploration of the impact of 2-hydroxypropyl-β-cyclodextrin treatment on lifespan and brain cholesterol metabolism in male mecp2 deficient mice</td>
<td>$156,180</td>
</tr>
<tr>
<td>Miscellaneous Pilot Studies</td>
<td></td>
<td>-$20,000</td>
<td></td>
</tr>
<tr>
<td>DiamiR</td>
<td>Yale University</td>
<td>microRNA biomarkers in Rett Syndrome</td>
<td>$26,815</td>
</tr>
<tr>
<td>David Katz, PhD</td>
<td>Case Western Reserve University</td>
<td>Preclinical Studies of LM22A-4 in Mouse Models of Rett Syndrome</td>
<td>$14,154</td>
</tr>
<tr>
<td>Jackson Labs</td>
<td></td>
<td>Development of mouse models</td>
<td>$42,052</td>
</tr>
<tr>
<td>Hermano Igo Krebs, PhD</td>
<td>Massachusetts Institute of Technology</td>
<td>Pilot Study</td>
<td>$8,000</td>
</tr>
</tbody>
</table>

**TOTAL AWARDS $8,741,782**
**2014**

**Monica Justice, PhD**
University of Toronto
*Identifying genetic modifiers of MECP2 in the mouse*
$715,680

**Jeffery Neul, MD, PhD**
Baylor College of Medicine
*Identification of genetic modifiers in Rett Syndrome*
$314,456

**Jeannie Lee, PhD**
Massachusetts General Hospital / Harvard University
*Re-awakening the silenced normal MECP2 allele with small molecules to treat Rett Syndrome*
$465,000

**Antonio Bedalov, PhD**
Fred Hutchinson Cancer Research Center
*Chemical genetic approach to reactivate the silenced MECP2 gene on the inactive X chromosome*
$280,000

**Terry Magnuson, PhD**
University of North Carolina, Chapel Hill
*Systems genetics approach toward understanding regulation of MECP2 expression*
$200,000

**David Katz, PhD**
Case Western Reserve University
*Preclinical studies of LM22A-4 in mouse models of Rett Syndrome*
$271,700

**Adrian Bird, PhD / Michael Greenberg, PhD / Gail Mandel, PhD**
University of Edinburgh / Harvard University / Oregon Health and Science University
*MECP2 Consortium*
$250,000

**Ali Khoshnan, PhD / Sarkis Mazmanian, PhD**
California Institute of Technology
*Exploring the link between MECP2 and gut physiology to test a novel probiotic therapy for Rett Syndrome*
$200,000

**Lucas Pozzo-Miller, PhD**
University of Alabama Birmingham
*Testing whether LM22A-4 improves hippocampal function in female MECP2 heterozygous mice*
$110,000

**Neurolixis**
*NLX-101 as a treatment for breathing disorders in Rett Syndrome*
$54,945

**Sung-Yon Kim, PhD**
Life Science Research Foundation
*Post doctoral fellowship*
$91,500

**Steven Gray, PhD**
University of Texas Southwestern Medical Center
*Supplement for gene therapy consortium*
$67,401

**Tom Frazier, PhD / David Katz, PhD / Daniel Sessler, MD, PhD**
Case Western Reserve University / Cleveland Clinic
*Low-dose ketamine for the treatment of Rett Syndrome*
$1,295,131

**Sasha Djukic, MD, PhD**
Albert Einstein College of Medicine
*Pharmacological treatment of Rett Syndrome with Lovastatin*
$403,000

**Sasha Djukic, MD, PhD**
Albert Einstein College of Medicine
*Supplement for copaxone clinical trial*
$47,000

**TOTAL AWARDS** $5,809,107
Debra Weese-Mayer, MD / Michael Carroll, PhD
Lurie Children’s Hospital of Chicago
Outlining the automatic signature of Rett Syndrome
$157,300

Nurit Ballas, PhD
Stony Brook University
Determine the proteome, secretome and transcript changes in astrocytes derived from human Rett patients iPSCs and their effect on interaction with human neurons
$20,000

DiamiR
microRNA biomarkers in Rett Syndrome
$6,768

Sasha Djukic, MD, PhD
Albert Einstein College of Medicine
Support for continuing work at the Rett Syndrome Center
$140,161

Stephen Turley, PhD
University of Texas Southwestern Medical Center
Exploration of the impact of 2-hydroxypropyl-B-cyclodextrin treatment on lifespan and brain cholesterol metabolism in male mecp2 deficient mice
$20,000

Recursion Pharmaceuticals
High content phenotypic screening of existing drugs for the treatment of Rett Syndrome
$25,000

Daniela Tropea, PhD
Trinity College Dublin
Expression of nuclear MeCP2 is dependent on neuronal stimulation and application of IGF1
$13,000

Miscellaneous Pilot Projects
$7,000

Huda Zoghbi, MD, PhD
Baylor College of Medicine
A forward genetic screen to identify druggable modulators of MECP2 levels
$414,065

Huda Zoghbi, MD, PhD
Baylor College of Medicine
Antisense oligonucleotide therapy for the treatment of MECP2 Duplication Syndrome
$230,000

2013

Adrian Bird, PhD / Michael Greenberg, PhD / Gail Mandel, PhD
University of Edinburgh / Harvard University / Oregon Health and Sciences University
MECP2 Consortium
$3,417,575

Stuart Cobb, PhD / Steven Gray, PhD / Brian Kaspar, PhD / Gail Mandel, PhD
University of Glasgow / University of North Carolina Chapel Hill / Nationwide Children’s Hospital / Oregon Health and Sciences University
Gene Therapy Consortium
$1,535,942

Michael Green, PhD
University of Massachusetts Medical School
Testing drugs that modulate X chromosome inactivation to reactivate the silent MECP2
$750,000

David Katz, PhD
Case Western Reserve University
Preclinical evaluation of therapeutics that modulate the NMDA pathway
$150,000

Jeannie Lee, PhD
Massachusetts General Hospital / Harvard University
An oligotherapeutics approach to treat Rett Syndrome
$100,000

Michela Fagiolini, PhD
Boston Children’s Hospital
Preclinical testing of selective novel NMDA receptor modulators
$126,741

Mark Bear
Massachusetts Institute of Technology
mGluR5 dependent synaptic protein synthesis in Rett Syndrome
$45,943

Bruria Ben Zeev, MD
Sheba Medical Center
Copaxone clinical trial
$197,962

Sasha Djukic, MD, PhD
Albert Einstein College of Medicine
Copaxone clinical trial
$412,370

TOTAL AWARDS $7,167,097
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Project Description</th>
<th>Award Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sasha Djukic, MD, PhD</td>
<td>Albert Einstein College of Medicine</td>
<td>Support for ongoing work at Rett Syndrome Center</td>
<td>$72,000</td>
</tr>
<tr>
<td>Huda Zoghbi, MD, PhD</td>
<td>Baylor College of Medicine</td>
<td>A forward genetic screen to identify druggable modulators of MeCP2 levels</td>
<td>$319,224</td>
</tr>
</tbody>
</table>

### 2012

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Project Description</th>
<th>Award Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Philpot, PhD</td>
<td>University of North Carolina Chapel Hill</td>
<td>A chemical genetic approach for activating the dormant gene associated with Rett Syndrome</td>
<td>$2,204,800</td>
</tr>
<tr>
<td>Jonathan Kipnis, PhD</td>
<td>University of Virginia</td>
<td>Immune modulation as a new therapeutic approach for Rett Syndrome</td>
<td>$720,000</td>
</tr>
<tr>
<td>John Bissonnette, PhD</td>
<td>Oregon Health and Sciences University</td>
<td>Respiration in MECP2 deficient mice</td>
<td>$59,842</td>
</tr>
<tr>
<td>Antonio Bedalov, PhD</td>
<td>Fred Hutchinson Cancer Research Center</td>
<td>Chemical genetic approach to reactivate the silenced MECP2 gene on the inactive X chromosome</td>
<td>$55,688</td>
</tr>
<tr>
<td>Andrew Pieper MD, PhD</td>
<td>University of Texas Southwestern Medical Center</td>
<td>In vivo identification of pharmacological agents for the treatment of Rett Syndrome</td>
<td>$69,000</td>
</tr>
</tbody>
</table>

### 2011

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Project Description</th>
<th>Award Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrian Bird, PhD / Michael Greenberg, PhD / Gail Mandel, PhD</td>
<td>University of Edinburgh / Harvard University / Oregon Health and Sciences University MECP2 Consortium</td>
<td>Investigating novel therapeutic approaches for Rett Syndrome</td>
<td>$1,940,441</td>
</tr>
<tr>
<td>Huda Zoghbi, MD, PhD</td>
<td>Baylor College of Medicine</td>
<td>Is MECP2 Duplication/Triplication Syndrome reversible?</td>
<td>$236,200</td>
</tr>
<tr>
<td>Huda Zoghbi, MD, PhD</td>
<td>Baylor College of Medicine</td>
<td>Identifying gene modifiers that ameliorate Rett Syndrome</td>
<td>$280,000</td>
</tr>
<tr>
<td>Monica Justice, PhD</td>
<td>Baylor College of Medicine</td>
<td>Identification of gene modifiers that ameliorate Rett Syndrome</td>
<td>$757,165</td>
</tr>
</tbody>
</table>

TOTAL AWARDS 2012: $4,235,266

TOTAL AWARDS 2011: $3,609,479
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Project Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monica Justice, PhD</td>
<td>Baylor College of Medicine</td>
<td>Identification of gene modifiers that ameliorate Rett Syndrome</td>
<td>$298,879</td>
</tr>
<tr>
<td>Jonathan Kipnis, PhD</td>
<td>University of Virginia</td>
<td>Immune modulation as a new therapeutic approach for Rett Syndrome</td>
<td>$440,000</td>
</tr>
<tr>
<td>Antonio Bedalov, PhD</td>
<td>Massachusetts Institute of Technology</td>
<td>A high-throughput screen to identify compounds that reactivate the functional MECP2 allele in Rett Syndrome</td>
<td>$300,000</td>
</tr>
<tr>
<td>Mark Bear, PhD</td>
<td>Massachusetts General Hospital / Harvard University</td>
<td>mGluR5 dependent synaptic protein synthesis in Rett Syndrome</td>
<td>$85,896</td>
</tr>
<tr>
<td>Huda Zoghbi, MD, PhD</td>
<td>Baylor College of Medicine</td>
<td>Interventional trials in mice models of Rett Syndrome and MECP2 disorders</td>
<td>$100,000</td>
</tr>
<tr>
<td>Marisa Bartolomei, PhD</td>
<td>University of Pennsylvania</td>
<td>Analysis of epigenetic modifications of the MECP2 locus</td>
<td>$41,255</td>
</tr>
<tr>
<td>Jeffrey Macklis, PhD</td>
<td>Harvard University</td>
<td>Vitamin D therapy for MECP2 target Irak1/NFkB dysregulation</td>
<td>$35,352</td>
</tr>
<tr>
<td>Sasha Djukic, MD, PhD</td>
<td>Albert Einstein College of Medicine</td>
<td>Support for ongoing work at Rett Syndrome Center</td>
<td>$66,710</td>
</tr>
<tr>
<td>Benjamin Philpot, PhD</td>
<td>University of North Carolina Chapel Hill</td>
<td>Respiration in MECP2 deficient mice</td>
<td>$10,000</td>
</tr>
<tr>
<td>John Bissonnette, PhD</td>
<td>Oregon Health and Sciences University</td>
<td>A high-throughput screen to identify compounds that reactivate the functional MECP2 allele in Rett Syndrome</td>
<td>$15,147</td>
</tr>
<tr>
<td>John Bissonnette, PhD</td>
<td>Oregon Health and Sciences University</td>
<td>A high-throughput screen to identify compounds that reactivate the functional MECP2 allele in Rett Syndrome</td>
<td>$15,147</td>
</tr>
</tbody>
</table>

**2010**

**TOTAL AWARDS $1,322,052**
2009

Monica Justice, PhD  
Baylor College of Medicine  
Identification of gene modifiers that ameliorate Rett Syndrome  
$236,038

Stavros Lomvardas  
University of California San Francisco  
Insight into MECP2 function raises therapeutic possibilities for Rett Syndrome  
$140,000

Huda Zoghbi, MD, PhD  
Baylor College of Medicine  
Interventional trials in mice models of Rett Syndrome and MECP2 disorders  
$100,000

Marisa Bartolomei, PhD  
University of Pennsylvania  
Analysis of epigenetic modifications of the MECP2 locus  
$40,000

Sasha Djukic, MD, PhD  
Albert Einstein College of Medicine  
Support for continuing work at the Rett Syndrome Center  
$36,645

TOTAL AWARDS $552,683

2008

Adrian Bird, PhD  
Baylor College of Medicine  
Identification of gene modifiers that ameliorate Rett Syndrome  
$236,038

Andrew Pieper, MD, PhD  
University of Texas Southwestern Medical Center  
In vivo identification of pharmacological agents for the treatment of Rett Syndrome  
$505,000

Monica Justice, PhD  
Baylor College of Medicine  
Identification of gene modifiers that ameliorate Rett Syndrome  
$253,000

Antonio Bedalov, PhD  
Fred Hutchinson Cancer Research Center  
Chemical genetic approach to reactivate the silenced MECP2 gene on the inactive X chromosome  
$140,000

TOTAL AWARDS $2,278,000